Fredun Pharmaceuticals Ltd — Important, 15-05-2026: Company Update

Fredun Pharmaceuticals has announced the launch of 'DAULCÉL', a premium wellness and longevity-focused brand. This strategic move expands the company into cellular aging and preventive healthcare, leveraging clinically backed NAD+ science to address growing demand for healthy aging and lifestyle-oriented wellness solutions. DAULCÉL enhances Fredun's specialty healthcare and wellness portfolio, reinforcing its diversification strategy and future-ready capabilities. For FY25, the company reported revenues of ₹ 456 Cr, EBITDA of ₹ 55 Cr, and PAT of ₹ 21 Cr.